Digirad applies for FDA clearance

Article

Digital gamma camera developer Digirad of San Diego hasfiled forregulatory clearance with the Food and Drug Administration forits lead product, Notebook Imager. If and when the applicationis cleared, Notebook Imager will become the first solid-stategamma

Digital gamma camera developer Digirad of San Diego hasfiled forregulatory clearance with the Food and Drug Administration forits lead product, Notebook Imager. If and when the applicationis cleared, Notebook Imager will become the first solid-stategamma camera to be marketed commercially.

Notebook Imager is a portable gamma camera that uses a cadmiumzinc telluride detector array rather than scintillation crystalsand photomultiplier tubes, as conventional Anger-style camerasdo (SCAN 6/5/96). Digirad hopes to receive FDA clearance and beginmarketing the system next year.

To help ramp up its manufacturing and product-testing effort,Digirad completed a $6 million financing issued to a group ofventure-capital firms. Proceeds from the funding will be usedto finish beta-site testing and develop a manufacturing capacityfor Notebook Imager. The funding was led by Sorrento Ventures,and included Kingsbury Capital Partners and several individualinvestors.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.